One or Two Immune Checkpoint Inhibitors?

Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use Antineoplastic Combined Chemotherapy Protocols Humans Ipilimumab / therapeutic use Lung Neoplasms / drug therapy Melanoma / drug therapy

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
09 Dec 2019
Historique:
entrez: 18 1 2020
pubmed: 18 1 2020
medline: 28 5 2020
Statut: ppublish

Résumé

The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors.

Identifiants

DOI: 10.1016/j.ccell.2019.11.005 PMID: 31951559
pubmed: 31951559
pii: S1535-6108(19)30525-2
doi: 10.1016/j.ccell.2019.11.005
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents 0
Ipilimumab 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

579-581

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Caroline Robert (C)

Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France; Paris-Saclay university, 63 Rue Gabriel Péri, 94270 Le Kremlin Bicêtre, France. Electronic address: caroline.robert@gustaveroussy.fr.

Emilie Lanoy (E)

Biostatistics and Epidemiology Unit, Gustave-Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France; CESP, INSERM, Paris-Saclay, Paris-Sud University UVSQ, 94805 Villejuif, France.

Benjamin Besse (B)

Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805 Villejuif, France; Paris-Saclay university, 63 Rue Gabriel Péri, 94270 Le Kremlin Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › One or Two Immune Checkpoint Inhibitors?
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › One or Two Immune Checkpoint Inhibitors?
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › One or Two Immune Checkpoint Inhibitors?
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › One or Two Immune Checkpoint Inhibitors?
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Ipilimumab › One or Two Immune Checkpoint Inhibitors?
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › One or Two Immune Checkpoint Inhibitors?
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › One or Two Immune Checkpoint Inhibitors?